Apontis Pharma AG (FRA:APPH)
10.55
0.00 (0.00%)
At close: Sep 9, 2025
Revenue by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
---|---|---|---|---|---|---|
Single Pills | 34.42M | Log In | Log In | Log In | Log In | Upgrade |
Single Pills Growth | 34.26% | Log In | Log In | Log In | Log In | Upgrade |
Asthma | 9.04M | Log In | Log In | Log In | Log In | Upgrade |
COPD (Respiratory Diseases) | 3.17M | Log In | Log In | Log In | Log In | Upgrade |
COPD (Respiratory Diseases) Growth | -60.23% | Log In | Log In | Log In | Log In | Upgrade |
Own Brands (Excluding Single Pills) | 1.47M | Log In | Log In | Log In | Log In | Upgrade |
Own Brands (Excluding Single Pills) Growth | -28.63% | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular | 395.00K | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular Growth | -65.17% | Log In | Log In | Log In | Log In | Upgrade |
Co-Marketing - Diabetes | - | Log In | Log In | Log In | Log In | Upgrade |
Co-Marketing - Diabetes Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Brands (without Single Pills) - Gynecology | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Brands (without Single Pills) - Gynecology Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Brands (without Single Pills) - Vascular | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Brands (without Single Pills) - Vascular Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Dafiro | - | Log In | Log In | Log In | Log In | Upgrade |
Dafiro Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
---|---|---|---|---|---|---|
Germany | 48.47M | Log In | Log In | Log In | Log In | Upgrade |
Germany Growth | 31.12% | Log In | Log In | Log In | Log In | Upgrade |